Skip to main content
letter
. 2020 Nov 3;16(3):446–448. doi: 10.2215/CJN.11470720

Table 1.

Epidemiology of AKI development among critically ill children who are coronavirus disease 2019 positive

Characteristics Total Coronavirus Disease 2019 Positive AKI No AKI
n (row %) 106 47 (44) 59 (56)
Date of enrollment
 Week 1 25 (24) 10 (21) 15 (25)
 Week 2 16 (15) 9 (19) 7 (12)
 Week 3 9 (9) 4 (9) 5 (9)
 Week 4 15 (14) 6 (13) 9 (15)
 Week 5 21 (20) 12 (26) 9 (15)
 Week 6 20 (19) 6 (13) 14 (24)
Age, yr, median (range) 11.0 (0.1–17.8) 10.5 (0.2–17.7) 11.0 (0.1–17.8)
Age categories
 Infants, 0–1 yr 13 (12) 4 (9) 9 (15)
 Toddlers, 1–5 yr 17 (16) 9 (19) 8 (14)
 Children, 5–13 yr 30 (28) 15 (32) 15 (25)
 Adolescents, ≥13 yr 46 (43) 19 (40) 27 (46)
Sex
 Females 52 (49) 26 (55) 26 (44)
 Males 54 (51) 21 (45) 33 (56)
Race
 White 37 (35) 17 (36) 20 (34)
 Black 34 (32) 17 (36) 17 (29)
 Asian 2 (2) 2 (4) 0 (0)
 Unknown 33 (31) 11 (23) 22 (37)
Ethnicity
 Non-Hispanic, non-Latino, non-Spanish 62 (59) 31 (66) 31 (53)
 Hispanic, Latino, Spanish 26 (25) 10 (21) 16 (27)
 Unknown 18 (17) 6 (13) 12 (20)
Locationa
 United States 100 (94) 43 (92) 57 (97)
 Western Europe 1 (0.9) 0 (0) 1 (2)
 Eastern Europe/Russia 5 (5) 4 (9) 1 (2)
Baseline eGFR, ml/min per 1.73 m2, median (range)b 112 (24–458) 128 (24–458) 105 (71–203)
Baseline serum creatinine, mg/dl, median (range)b 0.5 (0.1–1.7) 0.4 (0.1–1.7) 0.5 (0.1–1.1)
Admission serum creatinine, mg/dL, median (range)c 0.6 (0.1–5.6) 0.8 (0.1–5.6) 0.4 (0.1–1.1)
Peak serum creatinine, mg/dL, median (range)d 0.6 (0.1–5.6) 0.8 (0.3–5.6) 0.4 (0.1–1.1)
Any chronic condition 71 (67) 28 (60) 43 (73)
 No chronic condition 35 (33) 19 (40) 16 (27)
Common chronic conditions
 Seizures/epilepsy 16 (15) 8 (17) 8 (14)
 Congenital heart disease (corrected and uncorrected) 11 (10) 6 (13) 5 (8)
 Asthma 11 (10) 5 (11) 6 (10)
Admission reasons, multiple allowed
 Shock/hemodynamic instability 39 (37) 27 (58) 12 (20)
 Sepsis/infection 30 (28) 14 (30) 16 (27)
 Respiratory distress 52 (49) 22 (47) 30 (51)
 CNS symptoms 10 (9) 3 (6) 7 (12)
 Other 26 (25) 7 (15) 19 (32)
Nephrotoxin medication exposuree 43 (41) 20 (43) 23 (39)
Maximum percent fluid overload, median (range)f 3 (−10, 110) 2 (−10, 110) 5 (−5, 100)
Respiratory support
 None 48 (45) 19 (40) 29 (49)
 Noninvasive 28 (26) 13 (28) 15 (25)
 Invasive 30 (28) 15 (32) 15 (25)
Vasopressor support 31 (29) 19 (40) 12 (20)
ECMO 2 (2) 2 (4) 0 (0)
Mortalityg 6 (6) 3 (6) 3 (5)
Length of hospitalization <14 d 84 (79) 36 (77) 48 (81)
Length of hospitalization ≥14 d 12 (11) 8 (17) 4 (7)

Data are presented as N (column percentages) except where indicated. CNS, central nervous system; ECMO, extracorporeal membrane oxygenation.

a

Only regional location provided to maintain anonymity of centers/patients.

b

Baseline creatinine was missing for 71 patients, and height was missing for four; so, accurate baseline eGFR is only available for 31 (29.2%) patients. The remainder of baseline creatinine values were estimated by standard estimating equations (Materials and Methods).

c

Missing n=1.

d

Peak serum creatinine on the basis of weekly ascertainment. Therefore, true maximum peak creatinine may have been missed, and this may underestimate the true peak creatinine during the child’s hospitalization.

e

Nephrotoxic medications are defined on the basis of the large pediatric quality improvement initiative, Nephrotoxic Injury Negated by Just in time Action (5).

f

Fluid overload = (net fluid in − net fluid out)/intensive care unit admit weight.

g

The 28-d hospital mortality (missing n=1).